What Heartflow does

Heartflow is a medical technology company that develops an AI-powered platform for the non-invasive diagnosis and management of coronary artery disease (CAD). Its flagship product, Heartflow One, integrates four analytical modules — Roadmap Analysis (stenosis quantification), FFRCT Analysis (computational fluid dynamics-based fractional flow reserve), Plaque Analysis (plaque volume and characterization), and PCI Navigator (pre-procedural interventional planning) — into a single cloud-based workflow that processes standard coronary CT angiography (CCTA) scans into personalized 3D heart models. The underlying technology combines deep learning with proprietary computational fluid dynamics algorithms trained on approximately 273,000 patient records and validated against 110 million images.

Heartflow sells to hospitals, health systems, cardiology practices, and radiology departments through direct enterprise field sales and strategic partnerships, with platform adoption at 1,800+ institutions globally and 650,000+ patients managed to date. Revenue is generated primarily through insurance reimbursement rather than direct customer billing, with FFRCT Analysis covered under Category I CPT code 75580 (99.5% of US lives) and Plaque Analysis reimbursed under codes 75577 and 0623T-0626T (approximately 75% of US covered lives following UnitedHealthcare, Cigna, and Aetna coverage decisions). FY2025 revenue was $176 million, growing 40% year-over-year, with Q1 2026 revenue of $52.6 million (41% YoY growth) and full-year 2026 guidance of $218-222 million.

The company completed its NASDAQ IPO in August 2025 under ticker HTFL, raising $316.7 million. It operates as a remote-first organization with offices in San Francisco (headquarters), Austin, Rohnert Park, Mountain View, London, and Tokyo, and holds FDA 510(k) clearances, ISO 13485, ISO 27001, SOC 1, and HITRUST certifications. Competitive moats are anchored by 600+ global patents, Category I CPT reimbursement, ACC/AHA scientific statement endorsements, and an accumulating evidence base across 625+ peer-reviewed publications.

Name

Heartflow

Legal name

Heartflow, Inc.

Website

https://heartflow.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Heartflow is a publicly traded medical technology company that provides an AI-powered platform for non-invasive diagnosis and management of coronary artery disease, serving 1,800+ hospitals, health systems, and cardiology practices across the US, UK, and Japan with cloud-based CCTA analysis reimbursed by major insurers.

Ownership category

akta.pro rank

Product category

Cardiac Diagnostic Imaging Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)

akta.pro secondary industry

Cardiology Telemedicine Platforms (HLALAGAB)

Keywords

• Cardiac diagnostic imaging
• Coronary CTA analysis
• AI medical imaging
• Heart disease diagnostics
• Non-invasive cardiology

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. FFRCT Analysis Reimbursement: Heartflow generates revenue through reimbursement codes for its FFRCT Analysis, covered by Category I CPT code 75580 with 99.5% of US lives covered by Medicare and commercial insurers
2. Plaque Analysis Reimbursement: Revenue from plaque analysis services billed under CPT codes (75577/0623T-0626T), with coverage from Medicare, UnitedHealthcare, Cigna, Aetna, and Humana representing approximately 75% of US covered lives
3. Roadmap Analysis: Analysis provided with every CCTA sent to Heartflow, integrated into the platform subscription model

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Heartflow provides AI-powered analysis of coronary CT angiography (CCTA) scans through its Heartflow One platform, converting standard cardiac CT images into personalized 3D models of the heart. The platform delivers four integrated diagnostic tools: FFRCT Analysis for non-invasive blood flow assessment, Plaque Analysis for quantifying and characterizing coronary plaque, Roadmap Analysis for AI-enabled stenosis quantification, and PCI Navigator for pre-procedural interventional planning.

Product overview

Heartflow offers a unified platform called Heartflow One that provides AI-powered analysis for coronary artery disease management. The platform integrates four core products: FFRCT Analysis (for assessing blood flow and lesion-specific physiology), Plaque Analysis (for quantifying and characterizing coronary plaque), Roadmap Analysis (for efficient CCTA reading with consistent results), and PCI Navigator (for pre-procedural interventional planning). Together, these tools transform standard coronary CTA scans into personalized 3D models that help clinicians detect disease earlier, determine optimal treatment pathways, and manage patients for life.

Differentiator

Problem solved

Functional benefit

Brands

• Heartflow One: Integrated AI platform for managing coronary artery disease throughout the care continuum, including Roadmap Analysis, FFRCT Analysis, Plaque Analysis, and support services
• FFRCT Analysis
• Roadmap Analysis
• Plaque Analysis
• PCI Navigator

Products and services

• Heartflow One Unified AI-powered platform that transforms coronary CTA scans into personalized 3D heart models, integrating Roadmap Analysis, FFRCT Analysis, Plaque Analysis, and support services for comprehensive CAD management across the care continuum. Targeted at hospitals, health systems, and cardiology practices.
• FFRCT Analysis Non-invasive diagnostic tool using computational fluid dynamics and deep learning to assess blood flow anywhere in the coronary tree and determine the benefit of revascularization, achieving 0.94 AUC for non-invasive CAD diagnosis. Sold to hospitals, cardiology practices, and radiology departments and reimbursed under Category I CPT code 75580.
• Plaque Analysis AI-driven assessment that quantifies total plaque volume by type, determines plaque composition including high-risk non-calcified plaque, and delivers personalized preventive care recommendations with 95% agreement to invasive gold-standard IVUS. Sold to hospitals and cardiology practices and reimbursed under CPT codes 75577 and 0623T-0626T.
• Roadmap Analysis AI-enabled coronary stenosis quantification tool that efficiently reads every CCTA with consistent results across readers, boosting reading efficiency by up to 25% and improving agreement between CT readers by over 40%. Sold to hospitals, cardiology practices, and radiology departments.
• PCI Navigator AI-driven tool for pre-procedural planning of percutaneous coronary interventions (PCI), providing interventional cardiologists with detailed 3D models of coronary anatomy, plaque, and lesion physiology for improved procedural planning. Sold to hospitals and interventional cardiology practices.
• Heartflow Support Comprehensive support services including CCTA education, coding and reimbursement support, technology integration assistance, educational resources, peer-to-peer education, and case support to help institutions build and scale CCTA programs. Sold as a service wrap around the Heartflow One platform.

Quantifiable outcome

• 88% lower cardiovascular death rate at 3 years for patients with normal FFRCT
• +7 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• The Christ Hospital Health NetworkminorStrategic or Co-development Partner · 21 April 2026The Christ Hospital Health Network announced participation as one of 17 sites nationwide (and the only site in Ohio) in Heartflow's GAMEFILM Registry, a study focused on advancing understanding of heart disease in former professional athletes using Heartflow Plaque Analysis and coronary computed tomography angiography.
• Cardiovascular Associates of America (CVAUSA)coreStrategic or Co-development Partner · 24 March 2026CVAUSA, a network of over 460 cardiovascular physicians operating at 100+ clinic locations in 8 states serving 1.3 million patients annually, announced implementation of Heartflow's AI-powered diagnostic technology across its clinical network. The Heartflow One platform provides non-invasive coronary artery disease detection through personalized 3D modeling and plaque analysis using CCTA imaging.
• Advanced Diagnostics Healthcare System (ADHS)coreStrategic or Co-development Partner · 11 February 2026ADHS partnered with Heartflow to bring non-invasive coronary imaging technology to patients at River Oaks Hospital & Clinics and Advanced Dallas Hospital & Clinics in Texas. The collaboration aims to improve early cardiovascular disease detection and provide clearer diagnostic information to patients and physicians using AI-driven 3D modeling of coronary blood flow.
• Banner HealthcoreStrategic or Co-development Partner · 11 February 2026Banner Health formed a strategic partnership with HeartFlow to enhance cardiac diagnostics and procedures at its hospitals. The collaboration leverages HeartFlow's AI technology and PCI Navigator to improve patient assessment and interventional planning for coronary artery disease.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Cleerly: Cleerly is a direct competitor providing AI-powered coronary CTA analysis for plaque characterization and stenosis assessment, recently endorsed alongside Heartflow by Aetna. The two companies are currently in active patent litigation, underscoring their direct product overlap in non-invasive CAD diagnostics.
• Circle Cardiovascular Imaging: Circle CVI provides advanced cardiac MR, CT, and echocardiography post-processing software used by the same cardiology and radiology departments as Heartflow. It is a direct peer in cardiac imaging workflow software with comparable clinical decision-support positioning.

Broad incumbents

• GE HealthCare: GE HealthCare is a large incumbent in cardiac CT imaging hardware and post-processing software (Advantage Workstation, HeartStation). It competes with Heartflow by offering integrated cardiac CT analysis tools to the same hospital and cardiology customers, though as part of a much broader imaging portfolio.
• Philips: Philips offers cardiac CT post-processing, advanced visualization, and AI-enabled analysis tools through its IntelliSpace Portal. It serves the same cardiology and radiology departments as Heartflow and competes for clinical workflow share, though its offerings sit inside a broader imaging and patient monitoring portfolio.
• Siemens Healthineers: Siemens Healthineers provides cardiac CT scanners and the syngo.via post-processing platform with AI-driven cardiac analysis. It competes for the same hospital imaging budgets as Heartflow, with cardiac CT analysis as one component of a much larger diagnostic imaging portfolio.

Emerging players

• Elucid Bioimaging: Elucid develops AI software for non-invasive characterization of coronary plaque from CCTA, directly addressing the same plaque analysis workflow as Heartflow's Plaque Analysis product. It is a smaller emerging competitor focused specifically on plaque histology-style assessment.
• Aidoc: Aidoc is an AI platform for medical imaging that includes cardiac CT analysis capabilities and integrates with hospital PACS workflows. It competes for AI-imaging budget at the same health systems as Heartflow, though with a broader multi-organ imaging focus.
• Viz.ai: Viz.ai provides AI-driven clinical workflow and imaging analysis, with growing cardiology applications alongside its core neurology focus. It targets similar hospital AI budgets and integrates with PACS/EMR systems the same way Heartflow does.
• Us2.ai: Us2.ai provides AI-based automated analysis of echocardiograms for cardiac function and disease characterization. It is an adjacent cardiology AI peer addressing non-invasive cardiac imaging, but on ultrasound rather than CT, with partial overlap in cardiology workflow customers.
• Eko Health: Eko Health combines AI-enabled digital stethoscopes and cardiac analytics for earlier detection of heart disease. It is an emerging cardiology AI peer targeting earlier-stage screening and monitoring, complementing rather than directly competing with Heartflow's CT-based diagnostic workflow.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Heartflow
• Facebookfacebook.com/HeartFlow-832414017101512
• LinkedInlinkedin.com/company/heartflow-inc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds12 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heartflow